A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 57, Issue 2, 2007, Pages 168-174

  Grigorescu, Alexandru ^a   Ciuleanu, Tudor ^b   Firoiu, Elena ^c   Muresan, Delia Ruta ^c   Teodorescu, Gabriela ^c   Basson, Bruce R ^c  

^a Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c Targoviste County Hospital ^*  (Austria)

Author keywords

Cisplatin; Gemcitabine; Ifosfamide; Non small cell lung cancer (NSCLC); Vinorelbine

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; NAVELBINE;

ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GRANULOCYTOPENIA; HEART DISEASE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 34447273355     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.03.010     Document Type: Article

References (27)

1. NSCLC Collaborative Group. Chemotherapy in NSCLC: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311 (1995) 899-909
2. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic NSCLC. J Clin Oncol 17 1 (1999) 12-18
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Eastern Cooperative Oncology Group, comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Lorusso V., Carpagnano F., Frasci G., Panza N., Di Rienzo G., Cisternino M.L., et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18 (2000) 405-411
5. Lilenbaum R.C., Schwaartz M.A., Cano R., Krill E., Lutzky J., Blaustein A., et al. Gemcitabine (GEM) and navelbine (NVB) in advanced non-small cell lung cancer (NSCLC). Proceedings in ASCO, vol. 17 (1998) 494
6. Isokangas O.P., Knuuttila A., Halme M., Mantyla M., Lindstrom I., Nikkanen V., et al. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 10 (1999) 1059-1063
7. Esteban E., Fra J., Corral N., Valle M., Carrasco J., Sala M., et al. Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Invest New Drugs 20 (2002) 73-82
8. Laack E., Mende T., Benk J., Chemaissani A., Scholtze J., Lorenz C., et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. Eur J Cancer 37 (2001) 583-590
9. Chen Y.M., Perng R.P., Peng J.W., Liu T.W., Yang K.Y., Lin W.C., et al. A multi-centre phase II trial of gemcitabine (GEM) and vinorelbine (VRL) in patients (PTS) with advanced stage III-IV non-small cell lung cancer (NSCLC). Eur J Cancer 35 Suppl. 4 (1999) S259
10. Gatzemeier U., Manegold C., Eberhard W., Wilke H.J., Chomy F., Chomy P., et al. A phase II trial of gemcitabine and ifosfamide in NSCLC. Semin Oncol 24 3 Suppl. 8 (1997) S8-36-S8-38
11. Gatzemeier U., Manegold C., Eberhard W., Wilke H.J., Chomy F., Chomy P., et al. Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer. Semin Oncol 25 1 Suppl. 2 (1998) 15-18
12. Edelman M.J., Gandara D.R., Lau D.H., Lara P., Lauder I.J., and Tracy D. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92 (2001) 146-152
13. Rinaldi M., Noseda M.A., Lopez M., Cipri A., Spadoni M., Moreschi M., et al. Alternant chemotherapy (CT) with cisplatin, iphosphamide and mitomycin, vinorelbine in the the treatment of non-small cell lung cancer (NSCLC). Final results of a phase II cooperative study. Lung Cancer 18 Suppl. 1 (1997) 38
14. Seve P., Isaac S., Tredan O., Souquet J.P., Pacheco Y., Perol M., et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11 15 (2005) 5481-5486
15. Toffoli G., Frustaci S., Tumiotto L., Talamini R., Gherlinzoni F., Picci P., et al. Expression of MDR1 and GST-π in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 3 (1992) 63-69
16. World Health Organization. WHO handbook for reporting the results of Cancer treatment 48 (1979), World Health Organization, Geneva, Switzerland
17. Lachin J.M. Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 2 (1981) 93-113
18. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced NSCLC: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
19. Crino L., and Calandri C. Gemzar platinum combinations: phase III trials in non-small cell lung cancer. Lung Cancer 38 Suppl. 2 (2002) S9-S12
20. Georgoulias V., Papadakis E., Alexopoulos A., Tsiafaki X., Rapti A., Veslemes M., et al. Greek Oncology Cooperative Group (GOCG) for lung cancer platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357 (2001) 1478-1484
21. Kosmidis P., Mylonakis N., Nicolaides C., Kalophonos C., Samantas E., Boukovinas J., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 (2002) 3578-3585
22. Alberola V., Camps C., Provencio M., Isla D., Rosell R., Vadell C., et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21 (2003) 3207-3213
23. Rudd R.M., Gower N.H., Spiro S.G., Eisen T.G., Harper P.G., Littler J.A., et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23 (2005) 142-153
24. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Group trial. J Clin Oncol 18 (2000) 623-631
25. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
26. Van Meerbeeck J., Smit E., Lianes F.P., Schramel F., Lenz M.A., Debryne C., et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20 (2001) 308a [abstract 1228]
27. Pfister D, Johnson D, Azzoli C, Sause W, Smith T, Baker S, et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-53.